Clinical trials: Graft Rejection
Graft Rejection
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
- Trial name
- NCT01147302
- Testing
- C1 Esterase Inhibitor (Human)
- Where
- 5 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- Shire
Antibody-mediated Rejection, Kidney Transplant Rejection
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant Rejection, Graft Loss
- Trial name
- NCT04367610
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Istanbul University
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Implant or Graft; Rejection
Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy…
- Trial name
- NCT02152345
- Testing
- Belatacept, Tacrolimus, Mycophenolate
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Columbia University
Kidney Transplant Failure and Rejection, Immunosuppression
Long-term Outcomes After Conversion to Belatacept
belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients.
- Conditions
- Kidney Transplant Failure and Rejection, Immunosuppression, Graft Loss, Drug Effect Prolonged
- Trial name
- NCT04733131
- Testing
- Conversion to a belatacept regimen
- Volunteers
- 324 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Antibody-Mediated Graft Rejection
Cell-based Assays for Antibody-mediated Transplant Rejection
Goal: The goal of this study is to validate blood tests, which can detect antibody-mediated rejection (ABMR) after renal transplantation.
- Trial name
- NCT03916822
- Testing
- Alloantigen-specific B-cells
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Plexision
Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection
Cardiac Mitochondrial Function After Heart Transplantation
Studies have shown that cardiac function is affected immediately after heart transplantation (HTx), but seems to recover to some extent over the first year.
- Conditions
- Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection, Primary Graft Failure, Mitochondrial Function
- Trial name
- ENERGY-HTX (NCT04105803)
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- University of Aarhus
Acute Graft Rejection, Heart Transplantation
Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2
The investigators propose a simple and non-invasive method to monitor heart transplant patients with MRI. Its diagnostic and prognostic values have already been assessed in two monocentric studies.
- Trial name
- DRAGET (NCT02261870)
- Testing
- MRI T2 quantification
- Where
- 10 sites in France
- Volunteers
- 116 people
- Sponsor
- Central Hospital, Nancy, France
Kidney Transplantation, Graft Rejection
Study of Rituximab to Treat Chronic Renal Transplant Rejection
Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic…
- Conditions
- Kidney Transplantation, Graft Rejection, Immunosuppression
- Trial name
- RituxiCAN-C4 (NCT00476164)
- Testing
- Rituximab, Control arm
- Where
- 11 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- King's College London
Graft Rejection, Kidney Disease
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
This protocol facilitates the development of methods for determining whether transplant recipients have developed immune hyporesponsiveness or tolerance towards their allograft.
- Trial name
- NCT00001858
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Renal-urinary Impairment, Graft Rejection
Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients
BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow…
- Conditions
- Renal-urinary Impairment, Graft Rejection, Infection Episodes
- Trial name
- BKV-Pneumo (NCT04164576)
- Testing
- Transplant patients
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Cardiac Transplant Disorder, Cardiac Death
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Heart transplantation (HTx) is a procedure which is hindered by several complications. The HEARTS registry aims to allow the analysis of risk factors of all post-HTx complications.
- Conditions
- Cardiac Transplant Disorder, Cardiac Death, Heart Failure, Acute Cellular Graft Rejection
- Trial name
- HEARTS (NCT03393793)
- Volunteers
- 566 people
- Sponsor
- Lee S Nguyen
Acute Cellular Graft Rejection, Liver Transplant Rejection
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Our hypothesis is that budesonide will provide effective hepatic ISP that will replace prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and calcineurin-associated complications often observed in…
- Trial name
- BILT (NCT03315052)
- Testing
- Budesonide, Tacrolimus（FK506）, Mycophenolate Mofetil
- Sponsor
- Montefiore Medical Center
Acute Graft Rejection, Renal Failure Chronic Requiring Dialysis
Kidney Transplant Failure
Primary Hypotheses: 1. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have more deaths than patients who discontinue these drugs 2.
- Trial name
- NCT01296061
- Where
- Canada
- Volunteers
- 270 people
- Sponsor
- Ottawa Hospital Research Institute
Rejection, Graft Loss
Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients
This study will test whether selected allogeneic bone marrow derived MSCs are safe by assessing the composite end point Biopsy Proven Acute Rejection (BPAR)/ graft loss at 12 months.
- Trial name
- Neptune (NCT02387151)
- Testing
- mesenchymal stromal cells
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Acute Graft Rejection
Magnetic Resonance Elastography of Cardiac Transplant Rejection
Magnetic Resonance Elastography (MRE) for cardiac transplant patients.
- Trial name
- NCT02266914
- Testing
- Magnetic Resonance Elastography driver
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University
Cardiac Allograft Vasculopathy, Chronic Rejection of Cardiac Transplant
Heart Failure After Heart Transplantation Due to Chronic Rejection
This study will investigate the prevalence of allograft vasculopathy and unexplained graft dysfunction during long-term follow-up after heart transplantation. Risk factors as well diagnostic approaches will be investigated.
- Conditions
- Cardiac Allograft Vasculopathy, Chronic Rejection of Cardiac Transplant, Graft Dysfunction
- Trial name
- AVALON (NCT03808324)
- Testing
- Diagnostic investigations
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Sahlgrenska University Hospital
End Stage Renal Disease, Antibody Mediated Rejection
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of…
- Trial name
- BelatPilot (NCT02130817)
- Testing
- Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Implant or Graft; Rejection
Effect Of PRF Versus Xenograft In Closed Sinus Lift.
Indirect sinus lift with used PRF as a graft material versus xenograft
- Trial name
- NCT03684954
- Testing
- Prf
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mahmoud adel shaaban
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences